GlassScriptPhysician profile
Marilyn Vanhorn
NPI 1225292956
$10,660.93
in general payments reported to CMS, 2019-2025
57 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $1,263 · 2021: $1,476 · 2022: $1,732 · 2023: $1,957 · 2024: $1,634 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,201.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,025.20 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $905.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $902.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $876.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $687.90 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $549.86 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $454.08 | 2022-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $296.67 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $293.46 | 2022-2024 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $267.93 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $261.05 | 2022 | |
| Currax Pharmaceuticals LLC | $259.17 | 2019-2023 | Contrave |
| Axsome Therapeutics, INC. | $253.33 | 2022-2024 | Sunosi |
| Allergan, INC. | $219.61 | 2020 | |
| Merck Sharp & Dohme LLC | $201.67 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Vanhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.